Aktienanalyse zu IRadimed Corp (IRMD)IRMDIRadimed Corp

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories, disposables and services. Its MRidium 3870 MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium 3860+ MRI Compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to safely and predictably and other IV fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably on magnetic fields of over 30,000 gauss. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, IRadimed Corp is not a strong buy due to its low RSI of 29.196, indicating oversold conditions, and a forward P/E of 41.1523, suggesting the stock may be overvalued at this price. The recent quarterly dividend of $0.20 per share reflects stable cash flow, but the company reported stagnant revenue growth of only 0.5% year-over-year, which raises concerns about future performance. Additionally, the gross margin has declined to 74% from 78%, indicating rising production costs. The main risk is the declining gross margin, which could impact profitability significantly.

2 analysts cover IRMD: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.